Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection

Gene Therapy volume 6, pages 660–666 (1999)Cite this article

Abstract

Human immunodeficiency virus type I (HIV-1) encodes several proteins that are packaged into virus particles. Integrase (IN) is an essential retroviral enzyme, which has been a target for developing agents to inhibit virus replication. In previous studies, we showed that intracellular expression of single-chain variable antibody fragments (SFvs) that bind IN, delivered via retroviral expression vectors, provided resistance to productive HIV-1 infection in T-lymphocytic cells. In the current studies, we evaluated simian-virus 40 (SV40) as a delivery vehicle for anti-IN therapy of HIV-1 infection. Prior work suggested that delivery using SV40 might provide a high enough level of transduction that selection of transduced cells might be unnecessary. In these studies, an SV40 expression vector was developed to deliver SFv-IN (SV(Aw)). Expression of the SFv-IN was confirmed by Western blotting and immunofluorescence staining, which showed that >90% of SupT1 T-lymphocytic cells treated with SV(Aw) expressed the SFv-IN protein without selection. When challenged, HIV-1 replication, as measured by HIV-1 p24 antigen expression and syncytium formation, was potently inhibited in cells expressing SV40-delivered SFv-IN. Levels of inhibition of HIV-1 infection achieved using this approach were comparable to those achieved using murine leukemia virus (MLV) as a transduction vector, the major difference being that transduction using SV40 did not require selection in culture whereas transduction with MLV did require selection. Therefore, the SV40 vector as gene delivery system represents a novel therapeutic strategy for gene therapy to target HIV-1 proteins and interfere with HIV-1 replication.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Morsy MA, Mitani K, Clemens P, Caskey CT . Progress toward gene therapy J Am Med Assn 1993 270: 2338–2344

    Article  CAS  Google Scholar 

  2. Miller AD, Miller DG, Garcia JV, Lynch CM . Use of retroviral vectors for gene transfer and expression Meth Enzymol 1993 217: 581–599

    Article  CAS  Google Scholar 

  3. Mulligan RC . The basic science of gene therapy (review) Science 1993 260: 926–932

    Article  CAS  Google Scholar 

  4. Strayer DS . SV40 as an effective gene transfer vector in vivo J Biol Chem 1996 271: 24741–24746

    CAS  PubMed  Google Scholar 

  5. Strayer DS, Kondo R, Milano J, Duan L-X . Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells Gene Therapy 1997 4: 219–225

    Article  CAS  Google Scholar 

  6. Strayer DS, Milano J . SV40 mediates stable gene transfer in vivo Gene Therapy 1996 3: 581–587

    CAS  Google Scholar 

  7. Cullen BR . Mechanism of action of regulatory proteins encoded by complex retroviruses Microbiol Rev 1992 56: 375–394

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Debouck C . The HIV-1 protease as a therapeutic target for AIDS (review) AIDS Res Hum Retrovir 1992 8: 153–164

    Article  CAS  Google Scholar 

  9. Miller RH et al. Conference summary: novel HIV therapies – from discovery to clinical proof of concept AIDS Res Hum Retrovir 1996 12: 859–865

    Article  CAS  Google Scholar 

  10. Ridky T, Leis J . Development of drug resistance to HIV-1 protease inhibitors (Review) J Biol Chem 1995 270: 29621–29623

    Article  CAS  Google Scholar 

  11. Richman DD . Clinical significance of drug resistance in human immunodeficiency virus (Review) Clin Infect Dis 1995 21: S166–S169

    Article  Google Scholar 

  12. Dropulic B, Jeang KT . Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention (review) Hum Gene Ther 1994 5: 927–939

    Article  CAS  Google Scholar 

  13. Pomerantz RJ, Trono D . Genetic therapies for HIV infections: promise for the future (editorial) (review) AIDS 1995 9: 985–993

    Article  CAS  Google Scholar 

  14. Chen SY, Khouri Y, Bagley J, Marasco WA . Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody Proc Natl Acad Sci USA 1994 91: 5932–5936

    Article  CAS  Google Scholar 

  15. Duan L-X et al. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody Proc Natl Acad Sci USA 1994 91: 5075–5079

    Article  CAS  Google Scholar 

  16. Duan L-X, Pomerantz RJ . Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections Nucleic Acids Res 1994 22: 5433–5438

    Article  CAS  Google Scholar 

  17. Duan L-X et al. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains (published erratum appears in Hum Gene Ther 1997; 8: 510) Hum Gene Ther 1994 5: 1315–1324

    Article  CAS  Google Scholar 

  18. Duan L-X, Zhu M, Bagasra O, Pomerantz RJ . Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments Hum Gene Ther 1995 6: 1561–1573

    Article  CAS  Google Scholar 

  19. Duan L-X, Pomerantz RJ . Intracellular antibodies for HIV-1 gene therapy Sci Med 1997 3: 24–33

    Google Scholar 

  20. Levy-Mintz P et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase J Virol 1996 70: 8821–8832

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC . Anti-Tat gene therapy: a candidate for late-stage AIDS patients Gene Therapy 1995 2: 218–222

    CAS  PubMed  Google Scholar 

  22. Liu J, Woffendin C, Yang ZY, Nabel GJ . Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells Gene Therapy 1994 1: 32–37

    CAS  PubMed  Google Scholar 

  23. Poznansky MC et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat Hum Gene Ther 1998 9: 487–496

    Article  CAS  Google Scholar 

  24. Shaheen F et al. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle J Virol 1996 70: 3392–3400

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Sun LQ et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs Proc Natl Acad Sci USA 1995 92: 7272–7276

    Article  CAS  Google Scholar 

  26. Yu M et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 (published erratum appears in Proc Natl Acad Sci USA 1993; 90: 8303) Proc Natl Acad Sci USA 1993 90: 6340–6344

    Article  CAS  Google Scholar 

  27. Wu Y et al. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition (published correction appears in 1998; 72: 3505) J Virol 1996 70: 3290–3297

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Katz RA, Skalka AM . The retroviral enzymes (review) Ann Rev Biochem 1994 63: 133–173

    Article  CAS  Google Scholar 

  29. Bukrinsky M, Sharova N, Stevenson M . Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex J Virol 1993 67: 6863–6865

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Kondo R, Feitelson MA, Strayer DS . Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent Gene Therapy 1998 5: 575–582

    Article  CAS  Google Scholar 

  31. Butel JS, Jarvis DL . The plasma-membrane-associated form of SV40 large tumor antigen: biochemical and biological properties Biochem Biophys Acta 1986 865: 171–195

    CAS  PubMed  Google Scholar 

  32. Cicurel L, Croce CM . Antibody response to simian virus 40 tumor antigen in nude mice reconstituted with T cells J Immunol 1977 119: 850–854

    CAS  PubMed  Google Scholar 

  33. Crawford LV, Pim DC, Lane DP . An immunochemical investigation of SV40 T-antigens. 2. Quantitation of antigens and antibody activities Virology 1980 100: 314–325

    Article  CAS  Google Scholar 

  34. Law LW, Takemoto KK, Rogers MJ, Ting RC . Induction of simian virus 40 (SV40) transplantation immunity in mice by SV40-transformed cells of various species J Natl Cancer Inst 1977 59: 1523–1526

    Article  CAS  Google Scholar 

  35. Tevethia S . Characterization of hamster antibody reacting with papovavirus SV40 tumor antigen J Immunol 1967 98: 1257–1264

    CAS  PubMed  Google Scholar 

  36. Rund D et al. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions Hum Gene Ther 1998 9: 649–657

    Article  CAS  Google Scholar 

  37. Embretson J et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS Nature 1993 362: 359–362

    Article  CAS  Google Scholar 

  38. Strayer DS et al. Titering replication-defective virus for use in gene transfer BioTechniques 1997 22: 447–450

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, The Dorrance H Hamilton Laboratories, Center for Human Virology, Thomas Jefferson University, Philadelphia, PA, USA

    M BouHamdan, L-X Duan, R J Pomerantz & D S Strayer

  2. Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

    D S Strayer

Authors
  1. M BouHamdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L-X Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R J Pomerantz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D S Strayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

BouHamdan, M., Duan, LX., Pomerantz, R. et al. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther 6, 660–666 (1999). https://doi.org/10.1038/sj.gt.3300864

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300864

Keywords

This article is cited by

Search

Advanced search

Quick links